Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Roy Chowdhury S, Banerji V.

Oxid Med Cell Longev. 2018 Feb 28;2018:2426712. doi: 10.1155/2018/2426712. eCollection 2018. Review.

2.

Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.

Mejia EM, Zegallai H, Bouchard ED, Banerji V, Ravandi A, Hatch GM.

J Biol Chem. 2018 May 18;293(20):7564-7577. doi: 10.1074/jbc.RA117.001024. Epub 2018 Mar 21.

PMID:
29563154
3.

Associations between statin use and risk of non-Hodgkin lymphomas by subtype.

Ye X, Zhang G, Righolt C, Johnston JB, Banerji V, Gibson SB, Mahmud SM.

Int J Cancer. 2018 Aug 15;143(4):971-979. doi: 10.1002/ijc.31373. Epub 2018 Mar 30.

PMID:
29524215
4.

Metformin Is Not Associated with Incidence Risk of Non-Hodgkin Lymphomas among Diabetic Patients.

Ye X, Zhang G, Righolt C, Johnston JB, Banerji V, Gibson SB, Mahmud SM.

Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):610-612. doi: 10.1158/1055-9965.EPI-18-0012. Epub 2018 Mar 6.

PMID:
29511039
5.

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.

Ali AY, Wu X, Eissa N, Hou S, Ghia JE, Murooka TT, Banerji V, Johnston JB, Lin F, Gibson SB, Marshall AJ.

Leukemia. 2018 Jan 31. doi: 10.1038/s41375-018-0012-5. [Epub ahead of print]

PMID:
29479062
6.

Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine.

Perry AM, Matsuda K, Wadhwa V, Hewitt D, Almiski M, Johnston JB, Banerji V.

Blood Adv. 2017 May 30;1(14):899-902. doi: 10.1182/bloodadvances.2017004697. eCollection 2017 Jun 13.

7.

Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR.

Blood. 2017 May 4;129(18):2581-2584. doi: 10.1182/blood-2016-10-742437. Epub 2017 Feb 21. No abstract available.

8.

EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.

Mutz CN, Schwentner R, Aryee DNT, Bouchard EDJ, Mejia EM, Hatch GM, Kauer MO, Katschnig AM, Ban J, Garten A, Alonso J, Banerji V, Kovar H.

Oncotarget. 2017 Apr 11;8(15):24679-24693. doi: 10.18632/oncotarget.14976.

9.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

10.

Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.

Kost SE, Bouchard ED, LaBossière É, Ye X, Queau ML, Liang WS, Banerji V, Gibson SB, Katyal S, Johnston JB.

Leuk Res. 2016 Nov;50:63-71. doi: 10.1016/j.leukres.2016.09.016. Epub 2016 Sep 20.

PMID:
27683974
11.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE.

Leuk Lymphoma. 2017 Jun;58(6):1358-1365. doi: 10.1080/10428194.2016.1239259. Epub 2016 Oct 17.

PMID:
27750483
12.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

13.

Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population-based study.

Beiggi S, Banerji V, Deneka A, Griffith J, Gibson SB, Johnston JB.

Cancer Med. 2016 Jun;5(6):971-9. doi: 10.1002/cam4.559. Epub 2016 Feb 18.

14.

Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.

Dielschneider RF, Xiao W, Yoon JY, Noh E, Banerji V, Li H, Marshall AJ, Johnston JB, Gibson SB.

Cell Death Dis. 2014 Oct 2;5:e1439. doi: 10.1038/cddis.2014.391.

15.

On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.

Gehrke I, Bouchard ED, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, Banerji V.

Clin Cancer Res. 2014 Sep 15;20(18):4861-72. doi: 10.1158/1078-0432.CCR-14-0624. Epub 2014 Aug 29.

16.

Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study.

Beiggi S, Johnston JB, Seftel MD, Pitz MW, Kumar R, Banerji V, Griffith EJ, Gibson SB.

Br J Cancer. 2013 Sep 3;109(5):1287-90. doi: 10.1038/bjc.2013.381. Epub 2013 Jul 16.

17.

SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.

18.

Targeting metabolism and autophagy in the context of haematologic malignancies.

Banerji V, Gibson SB.

Int J Cell Biol. 2012;2012:595976. doi: 10.1155/2012/595976. Epub 2012 Jul 8.

19.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, Roti G, Aster JC, Hahn WC, Kung AL, Stegmaier K.

J Clin Invest. 2012 Mar;122(3):935-47. doi: 10.1172/JCI46465. Epub 2012 Feb 13.

20.

High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort.

Seftel MD, Demers AA, Banerji V, Gibson SB, Morales C, Musto G, Pitz MW, Johnston JB.

Leuk Res. 2009 Nov;33(11):1463-8. doi: 10.1016/j.leukres.2009.06.013. Epub 2009 Jul 5.

PMID:
19581000
21.

Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.

Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB.

Cell Signal. 2008 Jun;20(6):1198-208. doi: 10.1016/j.cellsig.2008.02.009. Epub 2008 Feb 19.

PMID:
18396013
22.

The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia.

Banerji V, Johnston JB, Seftel MD.

Transfus Apher Sci. 2007 Aug;37(1):57-62. Epub 2007 Oct 4. Review.

PMID:
17919979

Supplemental Content

Loading ...
Support Center